These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6131495)

  • 1. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of naloxone or levallorphan on serum prolactin concentrations and apomorphine-induced growth hormone secretion.
    Lal S; Nair NP; Cervantes P; Pulman J; Guyda H
    Acta Psychiatr Scand; 1979 Feb; 59(2):173-9. PubMed ID: 420037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.
    Nair NP; Lal S; Cervantes P; Yassa R; Guyda H
    Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
    Kolakowska T; Gelder M; Fraser S
    Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.
    Smith S; Wheeler MJ; Murray R; O'Keane V
    J Clin Psychopharmacol; 2002 Apr; 22(2):109-14. PubMed ID: 11910254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dopamine agonists in tardive dyskinesia.
    Smith RC; Tamminga CA; Haraszti J; Pandey GN; Davis JM
    Am J Psychiatry; 1977 Jul; 134(7):763-8. PubMed ID: 869053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormones, dopamine receptors and schizophrenia.
    Meltzer HY; Busch D; Fang VS
    Psychoneuroendocrinology; 1981; 6(1):17-36. PubMed ID: 7244055
    [No Abstract]   [Full Text] [Related]  

  • 13. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 14. An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.
    Mielke DH; Gallant DM; Kessler C
    Am J Psychiatry; 1977 Dec; 134(12):1371-5. PubMed ID: 21571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication.
    Cotes PM; Crow TJ; Johnstone EC; Bartlett W; Bourne RC
    Psychol Med; 1978 Nov; 8(4):657-65. PubMed ID: 364517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
    Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
    Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia.
    Jeste DV; Neckers LM; Wagner RL; Wise CD; Staub RA; Rogol A; Potkin SG; Bridge TP; Wyatt RJ
    J Clin Psychiatry; 1981 Feb; 42(2):75-7. PubMed ID: 6109719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lithium on hypothalamic-pituitary dopaminergic function.
    Lal S; Nair NP; Guyda H
    Acta Psychiatr Scand; 1978 Jan; 57(1):91-6. PubMed ID: 636903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.